Trial Profile
A Phase I, Randomized, Single-Blind, Single-Dose, Three-Arm, Parallel-Group Study Assessing the Pharmacokinetic Similarity of Biosimilar ABP215 to Bevacizumab Reference Product Sourced from the US and the EU in Healthy Adult Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Dec 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Breast cancer; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma
- Focus First in man; Pharmacokinetics
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 18 May 2015 New trial record